Tirzepatide 5mg
Tirzepatide 5mg early-escalation research vial — common mid-low dose for incretin-pathway and metabolic research studies.
Bulk / Wholesale Inquiry
10+ vials · OEM / Private Label · Cold-chain Export Shipping
Get Factory Quote on WhatsAppVolume Pricing
Discounts applied via WhatsApp quote for qualified research / clinic inquiries.
Tirzepatide 5mg is widely used in research protocols as the first escalation dose after the 2.5mg initiation phase. Each vial contains ≥99% pure lyophilized peptide for reconstitution, supporting in-vitro investigation of dual GIP/GLP-1 receptor activity, glucose-dependent insulin release, and downstream metabolic markers.
Key Benefits
- Common early-escalation research dose
- ≥99% HPLC + MS verified purity
- Dual GIP/GLP-1 receptor agonist
- Lyophilized powder, lot-matched COA included
- Stable cold-chain handling from facility to lab
- Suitable for week-4 protocol escalation models
Scientific Background
The 5mg dose corresponds to the most frequently cited early-escalation strength in tirzepatide research literature. At this concentration, both GIP and GLP-1 receptor pathways show measurable activation in metabolic research models without saturating either pathway, making it useful for mechanism-of-action studies.
Educational Display Only
This product information is for educational purposes. Always consult licensed healthcare providers for personalized medical advice.
Frequently Asked Questions
Related Products
NAD+
Cellular health supplement supporting NAD+ levels, a crucial coenzyme involved in energy metabolism and cellular repair processes.
Available: 100mg, 200mg, 500mg
Semaglutide
GLP-1 receptor agonist for metabolic health optimization, supporting healthy weight management and glucose metabolism.
Available: 0.25mg, 0.5mg, 1mg
Tirzepatide
Dual GIP/GLP-1 receptor agonist representing the next generation of metabolic health therapeutics.
Available: 2.5mg, 5mg, 7.5mg, 15mg, 20mg, 30mg